Core Insights - Emergent BioSolutions has received FDA approval for a new carrying case for its NARCAN® Nasal Spray, aimed at enhancing accessibility and encouraging individuals to carry the life-saving medication during opioid emergencies [1][3] Product Development - The new packaging for NARCAN® Nasal Spray includes two blister packs and a Quick Start Guide, designed to be compact, discreet, and durable [1] - The carrying case aims to integrate seamlessly into daily life, addressing the low carry rate of the medication, which is currently at only 10% among the general consumer population [3] Consumer Insights - A survey conducted by Emergent revealed that 74% of consumers prefer a discreet carrying case over standard packaging, with this preference rising to 81% among college students, a high-risk group for opioid misuse [2] Market Impact - Since its prescription launch in 2016, over 85 million doses of NARCAN® have been distributed across the U.S. and Canada, indicating significant market penetration and demand for opioid overdose reversal solutions [4]